

Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023-04701 Filed 3-7-23; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—CE23-008, Research Grants to Develop and Validate a Prognostic Tool of Mental Health Sequelae After Traumatic Brain Injury for Adolescent Patients (U01); Amended Notice of Closed Meeting

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—CE23-008, *Research Grants to Develop and Validate a Prognostic Tool of Mental Health Sequelae After Traumatic Brain Injury for Adolescent Patients (U01)*, March 14, 2023, 8:30 a.m., EDT-5:30 p.m., EDT, Web Conference, in the original FRN. The meeting was published in the **Federal Register** on January 20, 2023, Volume 88, Number 13, page/s/ 3743.

The meeting is being amended to begin the meeting later and should read as follows:

Date: March 14, 2023.

Time: 10:00 a.m.–6:00 p.m. (EDT).

Place: Videoconference.

The meeting is closed to the public.

FOR FURTHER INFORMATION CONTACT:

Carlisha Gentles, PharmD, BCPS, CDCES, Scientific Review Officer, National Center for Injury Prevention and Control, CDC, 4770 Buford Highway NE, Mailstop F-63, Atlanta, Georgia 30341, Telephone: (770)488-1504; Email: CGentles@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and

Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023-04696 Filed 3-7-23; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—RFA-TS-23-001: Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS); Amended Notice of Closed Meeting

Notice is hereby given of a change in the meeting of the

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—RFA-TS-23-001: *Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS)*; April 11, 2023, 8:30 a.m.–5:30 p.m., EDT, Videoconference, in the original FRN. The meeting was published in the **Federal Register** on January 18, 2023, Volume 88, Number 11, page 2921.

The meeting is being amended to begin the meeting later and should read as follows:

Date: April 11, 2023.

Time: 10:00 a.m.–5:00 p.m. (EDT).

Place: Videoconference.

The meeting is closed to the public.

FOR FURTHER INFORMATION CONTACT:

Carlisha Gentles, PharmD, BCPS, CDCES, Scientific Review Officer, National Center for Injury Prevention and Control, CDC, 4770 Buford Highway NE, Mailstop F-63, Atlanta, Georgia 30341, Telephone (770)488-1504, Email: CGentles@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023-04699 Filed 3-7-23; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—RFA-PS23-001, Increasing PrEP Use Among Disproportionately Affected Populations in the United States and RFA-PS23-003, Exploring Preferences for Long-Acting Antiretroviral Therapies (LA-ART) in a Community-Based Sample of Priority Populations Living With HIV Who Are Disproportionately Affected; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—RFA-PS23-001, *Increasing PrEP Use Among Disproportionately Affected Populations in the United States and RFA-PS23-003, Exploring Preferences for Long-Acting Antiretroviral Therapies (LA-ART) in a Community-Based Sample of Priority Populations Living with HIV Who are Disproportionately Affected*, May 11–12, 2023, 10 a.m.–5 p.m., EDT, Teleconference, Centers for Disease Control and Prevention, Room 1077, 8 Corporate Blvd., Atlanta, GA 30329, in the original FRN. The meeting was published in the **Federal Register** on February 13, 2023, Volume 88, Number 29, page/s/ 9288–9289.

The meeting is being amended to change the title of RFA-PS23-001, *Increasing PrEP Use Among Disproportionately Affected Populations in the United States to RFA-PS23-001, Increasing PrEP Use Among Black Cisgender Women in the United States (HerPrEP) and to remove RFA-PS23-003, Exploring Preferences for Long-Acting Antiretroviral Therapies (LA-ART) in a Community-Based Sample of Priority Populations Living with HIV Who are Disproportionately Affected and replace with RFA-PS23-005, Expanding Rapid Initiation of Antiretroviral Therapy in Non-traditional Settings: Emergency Department*. The date of the teleconference will also change and should read as follows:

Date: May 24–25, 2023.

Place: Teleconference, Centers for Disease Control and Prevention, Room 1077, 8 Corporate Blvd., Atlanta, GA 30329.

The meeting is closed to the public.

FOR FURTHER INFORMATION CONTACT:

Gregory Anderson, M.S., M.P.H., Scientific Review Officer, National